Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

terminated120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

NCT04960202
completedphase_1

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895
completedphase_1

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

NCT05005312
terminatedphase_2

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

NCT05011513
completedphase_2

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

NCT05047601

Clinical Trials (5)

Showing 5 of 5 trials
NCT04960202Phase 2

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Completed
NCT05263895Phase 1

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

Completed
NCT05005312Phase 1

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Completed
NCT05011513Phase 2

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Terminated
NCT05047601Phase 2

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5